Your browser is no longer supported. Please, upgrade your browser.
INSM [NASD]
Insmed Incorporated
Index- P/E- EPS (ttm)-2.60 Insider Own0.60% Shs Outstand101.62M Perf Week7.76%
Market Cap3.74B Forward P/E- EPS next Y-2.78 Insider Trans-44.61% Shs Float100.82M Perf Month-10.61%
Income-244.90M PEG- EPS next Q-0.71 Inst Own- Short Float9.51% Perf Quarter1.37%
Sales168.70M P/S22.14 EPS this Y28.70% Inst Trans0.32% Short Ratio11.08 Perf Half Y36.86%
Book/sh3.51 P/B10.32 EPS next Y-3.40% ROA-31.10% Target Price50.80 Perf Year59.72%
Cash/sh5.71 P/C6.34 EPS next 5Y- ROE-79.60% 52W Range12.09 - 42.71 Perf YTD8.86%
Dividend- P/FCF- EPS past 5Y-10.40% ROI-38.20% 52W High-15.15% Beta2.35
Dividend %- Quick Ratio7.40 Sales past 5Y- Gross Margin77.60% 52W Low199.75% ATR1.90
Employees435 Current Ratio8.00 Sales Q/Q12.10% Oper. Margin- RSI (14)51.97 Volatility6.54% 5.50%
OptionableYes Debt/Eq1.03 EPS Q/Q7.90% Profit Margin- Rel Volume0.78 Prev Close37.37
ShortableYes LT Debt/Eq1.03 EarningsOct 29 BMO Payout- Avg Volume864.71K Price36.24
Recom1.80 SMA203.22% SMA50-1.57% SMA20021.15% Volume672,282 Change-3.02%
Dec-17-20Initiated Berenberg Buy $48
Oct-12-20Resumed Stifel Buy $44
Sep-03-19Initiated Goldman Buy $30
Apr-09-19Reiterated H.C. Wainwright Buy $43 → $52
Feb-15-19Upgrade JMP Securities Mkt Perform → Mkt Outperform $40
Jan-17-19Upgrade Goldman Neutral → Buy
Jan-02-19Initiated Canaccord Genuity Buy $20
Aug-06-18Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jul-23-18Initiated Goldman Neutral $32
Apr-23-18Upgrade Credit Suisse Neutral → Outperform
Mar-21-18Initiated Morgan Stanley Overweight $39
Jan-18-18Initiated Credit Suisse Neutral $31
Sep-05-17Reiterated Evercore ISI Outperform $28 → $40
Aug-17-17Initiated Evercore ISI Outperform $28
Jul-11-17Initiated Robert W. Baird Outperform $23
Mar-15-16Initiated Stifel Buy $23
Nov-09-15Downgrade UBS Buy → Neutral $35 → $18
Oct-06-15Reiterated H.C. Wainwright Buy $30 → $35
Jun-09-15Initiated Citigroup Neutral $27
Mar-26-14Reiterated HC Wainwright Buy $25 → $30
Jan-05-21 08:00AM  
Jan-04-21 08:00AM  
Dec-29-20 08:30AM  
Dec-23-20 02:59AM  
Dec-22-20 08:30AM  
Dec-16-20 09:18AM  
08:30AM  
Dec-15-20 08:30AM  
Dec-14-20 09:59AM  
Dec-04-20 08:00AM  
Dec-03-20 08:50AM  
Dec-02-20 08:00AM  
Nov-29-20 06:44AM  
Nov-24-20 08:00AM  
Nov-13-20 08:00AM  
Nov-06-20 08:00AM  
Nov-02-20 08:00AM  
05:29AM  
Oct-31-20 10:58AM  
Oct-29-20 09:05AM  
08:45AM  
07:30AM  
06:30AM  
Oct-28-20 07:37AM  
Oct-27-20 08:30AM  
Oct-22-20 12:33PM  
11:48AM  
Oct-20-20 08:30AM  
Oct-02-20 08:00AM  
Oct-01-20 08:30AM  
Sep-30-20 08:00AM  
Sep-29-20 08:30AM  
Sep-24-20 08:30AM  
Sep-16-20 05:11PM  
11:09AM  
08:00AM  
Sep-15-20 08:30AM  
Sep-09-20 04:05PM  
Sep-08-20 08:30AM  
Sep-07-20 12:25PM  
11:24AM  
Sep-04-20 08:00AM  
Sep-03-20 08:30AM  
Sep-01-20 08:30AM  
Aug-26-20 01:11PM  
Aug-20-20 04:01PM  
Aug-14-20 08:30AM  
Aug-11-20 12:33PM  
12:32PM  
08:30AM  
Aug-07-20 08:00AM  
Aug-06-20 10:35AM  
07:30AM  
Aug-03-20 12:30PM  
Jul-30-20 12:33PM  
Jul-28-20 08:30AM  
Jul-27-20 08:30AM  
08:00AM  
Jul-24-20 08:25AM  
07:36AM  
Jul-15-20 01:15PM  
Jul-07-20 08:00AM  
Jul-06-20 08:00AM  
Jun-29-20 08:30AM  
Jun-28-20 05:26PM  
Jun-24-20 04:01PM  
Jun-23-20 04:03PM  
Jun-19-20 11:58AM  
Jun-08-20 08:00AM  
Jun-05-20 08:00AM  
May-26-20 08:00AM  
May-25-20 01:15PM  
May-20-20 09:29AM  
May-19-20 09:47AM  
May-07-20 10:46AM  
08:00AM  
May-05-20 08:00AM  
08:00AM  
May-04-20 04:01PM  
06:49AM  
May-01-20 03:01PM  
Apr-30-20 09:05AM  
08:58AM  
07:30AM  
Apr-29-20 09:47AM  
Apr-23-20 12:32PM  
06:00AM  
Apr-20-20 08:00AM  
Apr-13-20 09:12AM  
Apr-07-20 03:33PM  
Apr-03-20 08:00AM  
Apr-02-20 08:00AM  
Mar-17-20 08:48AM  
Mar-16-20 04:01PM  
Mar-05-20 08:00AM  
Mar-04-20 08:00AM  
Mar-02-20 04:56PM  
Feb-27-20 08:13AM  
Feb-26-20 08:00AM  
Feb-25-20 08:55AM  
Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients in the United States. It also develops INS1007, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug for the treatment of rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lewis WilliamChair&Chief Executive OfficerDec 22Option Exercise3.4050,000170,000214,787Dec 23 04:15 PM
Lewis WilliamChair&Chief Executive OfficerDec 22Sale36.5750,0001,828,665164,787Dec 23 04:15 PM
ALTOMARI ALFREDDirectorDec 07Sale39.5720,000791,40020,938Dec 09 04:09 PM
SHAROKY MELVIN MDDirectorNov 19Sale39.484,000157,9207,714Nov 20 04:09 PM
Lewis WilliamChair&Chief Executive OfficerNov 06Option Exercise14.2835,000499,963164,787Nov 06 06:10 PM
Pellizzari Christine AChief Legal OfficerNov 05Option Exercise12.0239,654476,808134,002Nov 05 06:17 PM
Pellizzari Christine AChief Legal OfficerNov 04Option Exercise12.5830,000377,400110,013Nov 05 06:17 PM
Lewis WilliamChair&Chief Executive OfficerNov 04Option Exercise3.40200,000680,000179,523Nov 06 06:10 PM
Pellizzari Christine AChief Legal OfficerNov 04Sale34.2830,0001,028,29794,348Nov 05 06:17 PM
Lewis WilliamChair&Chief Executive OfficerNov 04Sale34.03200,0006,805,402129,787Nov 06 06:10 PM
Pellizzari Christine AChief Legal OfficerNov 03Option Exercise11.14113,7961,267,687132,744Nov 05 06:17 PM
Pellizzari Christine AChief Legal OfficerNov 03Sale32.52113,7963,700,84894,348Nov 05 06:17 PM
SHAROKY MELVIN MDDirectorSep 15Sale30.3310,000303,3009,900Sep 16 06:56 PM
SHAROKY MELVIN MDDirectorSep 15Sale31.039,900307,197236,890Sep 16 06:56 PM
SHAROKY MELVIN MDDirectorSep 14Sale30.701003,07019,900Sep 16 06:56 PM
Schaeffer Orlov S NicoleChief People Strategy OfficerAug 12Option Exercise11.874,46552,99639,227Aug 13 04:11 PM
Schaeffer Orlov S NicoleChief People Strategy OfficerAug 12Sale28.804,465128,57835,227Aug 13 04:11 PM
Schaeffer Orlov S NicoleChief People Strategy OfficerAug 11Option Exercise6.963,76126,17738,988Aug 13 04:11 PM
Schaeffer Orlov S NicoleChief People Strategy OfficerAug 11Sale30.073,761113,09335,227Aug 13 04:11 PM
SORIANO JOHNChief Compliance OfficerAug 10Option Exercise13.9152,046723,96077,259Aug 12 05:17 PM
SORIANO JOHNChief Compliance OfficerAug 10Sale30.2952,0461,576,47325,213Aug 12 05:17 PM